Patents Assigned to Temple University
  • Automated system for high-throughput electrophoretic separations
    Patent number: 6905585
    Abstract: A cassette is disclosed for use in performing electrophoretic separations on a solid substrate. The cassette includes reservoirs for containing buffer, electrodes for receiving electrical current and a substrate support. The cassette is designed to connect with external fluid and electrical sources. A method of conducting electrophoresis separation in both one and two dimensions using a cassette is also disclosed. Furthermore, a novel apparatus for use in performing electrophoresis separation is disclosed. The apparatus is preferably of modular construction with a docking station for receiving a cassette.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: June 14, 2005
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventor: Antonio M. Goncalves
  • Human antithrombin IIIs and methods related thereto
    Patent number: 6878813
    Abstract: The present invention discloses modified antithrombin III compounds and methods. The amino acid compounds of the present invention are useful in treating blood clotting disorders, as well as other disease states associated with enzymes in the coagulation pathway.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: April 12, 2005
    Assignees: Temple University - of the Commonwealth System of Higher Education, University of Utah Research Foundation
    Inventors: Susan C. Bock, Veronique Picard, Pedram Zendehrouh
  • Inhibition of angiogenesis by high molecular weight kininogen domain 3 peptide analogs
    Patent number: 6869931
    Abstract: Peptide analogs the high molecular weight kininogen domain 3 are potent inhibitors of angiogenesis. The peptides have the formula (a) X1-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-X2, (b) X3-Cys-Val-Gly-Cys-X4, (c) X5-Leu-Asp-X7-Asn-Ala-Glu-Val-Tyr-X6, or (d) Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-X7-Ser-Lys-Glu-Ser wherein: X1, X2, X3, X4, X5, and X6 are from zero to twelve amino acids, independently the same or different, more preferably from zero to six amino acids, and; X7 is Ala or Cys. The peptides may also comprise biologically active fragments of high molecular weight kininogen domain 3. Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: March 22, 2005
    Assignee: Temple University - Of The Commonwealth System of Higher Education
    Inventor: Keith R. McCrae
  • Ketamine treatment of restless legs syndrome
    Patent number: 6855735
    Abstract: The present invention is directed to a method for treating symptoms associated with Restless Legs Syndrome (RLS). The method includes administering to a warm-blooded animal in need of such treatment a dose of ketamine sufficient to alleviate symptoms associated with RLS.
    Type: Grant
    Filed: March 20, 2002
    Date of Patent: February 15, 2005
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventor: Robert Friedman
  • (Z)-styrylbenzylsulfones and pharmaceutical uses thereof
    Patent number: 6833480
    Abstract: Substituted (Z)-styrylbenzyl sulfones of the formulae (I, II, III, IV), pharmaceutically acceptable salts thereof, and compositions thereof are provided as cell antiproliferative agents, including, for example, anticancer agents.
    Type: Grant
    Filed: August 21, 2003
    Date of Patent: December 21, 2004
    Assignee: Temple University - Of The Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Method and apparatus for increasing and modulating the yield shear stress of electrorheological fluids
    Patent number: 6827822
    Abstract: A method for increasing and/or modulating the yield shear stress of an electrorheological fluid includes applying a sufficient electric field to the fluid to cause the formation of chains of particles, and then applying a sufficient pressure to the fluid to cause thickening or aggregation of the chains. An apparatus for increasing and/or modulating the transfer or force or torque between two working structures includes an electrorheological fluid and electrodes through which an electric field is applied to the fluid such that particles chains of particles are formed in the fluid and, upon application of pressure to the fluid, the chains thicken or aggregate and improve the force or torque transmission.
    Type: Grant
    Filed: November 9, 2001
    Date of Patent: December 7, 2004
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Rongjia Tao, Yucheng Lan, Xiaojun Xu, Edward Kaczanowicz
  • Radiolabeled vasoactive intestinal peptide analogs for imaging and therapy
    Patent number: 6824759
    Abstract: This invention relates to a radiodiagnostic agent to image tumors. A composition for a tumor imaging agent, a method and kit for preparing a tumor imaging agent, and a radiolabeling reagent for preparing the tumor imaging agent are provided.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: November 30, 2004
    Assignees: Thomas Jefferson University, Temple University - of the Commonwealth System of Higher Education
    Inventors: Madhukar L. Thakur, M. V. Ramana Reddy
  • (E)-styryl sulfone anticancer agents
    Publication number: 20040229959
    Abstract: (E)-styryl benzylsulfones of formula I are useful as anticancer agents: 1
    Type: Application
    Filed: May 18, 2004
    Publication date: November 18, 2004
    Applicant: Temple University - Of The Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M.V. Ramana Reddy
  • EC-3, an inhibitor of &agr;4&bgr;1 and &agr;4&bgr;7 integrins
    Patent number: 6818617
    Abstract: This invention relates to the identification, purification, and characterization of a novel heterodimeric disintegrin, EC-3, from Echis carinatus viper venom. EC-3 inhibits &agr;4 integrins in an RGD-independent manner. The invention further relates to methods of using EC-3, or a biologically active fragment or derivative thereof, to inhibit the interaction between cells expressing &agr;4 integrins and cellular ligands.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: November 16, 2004
    Assignee: Temple University- Of The Commonwealth System of Higher Education
    Inventors: Stefan Niewiarowski, Cezary Marcinkiewicz
  • Methods for cancer prognosis and screening antiproliferative agents
    Publication number: 20040203067
    Abstract: The invention provides prognostic methods which comprise determining the level of expression of the gene c-fyn, or the level of activated STAT-3 protein. Because the relative level of c-fyn expression and level of activated STAT-3 protein correlate with the presence of malignant potential and therefore patient prognosis, these markers may be used to make treatment decisions, to predict patient outcome, and to predict the risk of cancer in disease-free individuals. The invention further provides a method for identifying anticancer drugs in which inhibitors of cell proliferation are identified as inhibitors of Src-mediated STAT phosphorylation.
    Type: Application
    Filed: May 13, 2004
    Publication date: October 14, 2004
    Applicant: Temple University - Of The Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, Priya Chaturvedi, M.V. Ramana Reddy, John R. Jenkins
  • (E)-styryl sulfone anticancer agents
    Patent number: 6787667
    Abstract: (E)-styryl benzylsulfones of formula I are useful as anticancer agents: wherein R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, fluoro, chloro, iodo, bromo, C1-C6 alkyl, C1-C4 alkoxy, nitro, cyano and trifluoromethyl, with the proviso that (a) R1, R2 , and R3 not all hydrogen when R4 is 2-chloro or 4-chloro; (b) when R1 and R3 are hydrogen and R2 is 4-bromo or 4-chloro, then R4 may not be 4-chloro, 4-fluoro or 4-bromo; (c) when R1 and R3 are hydrogen and R2 is 4-fluoro, then R4 may not be 4-fluoro or 4-bromo, (d) when R1 is hydrogen, and R4 is 2-fluoro, the R2 and R3 may not be 4-fluoro; and (e) when R1 is hydrogen and R3 is 4-hydrogen, 4-chloro, 4-bromo, 4-methyl or 4-methoxy, and R4 is 2-hydrogen, 2-chloro, or 2-fluoro; then R2 may not be 4-hydrogen, 4-chloro, 4-fluoro, or 4-bromo.
    Type: Grant
    Filed: June 16, 2003
    Date of Patent: September 7, 2004
    Assignee: Temple University - of the Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Polymeric hemoglobin mutants
    Patent number: 6780892
    Abstract: Human &bgr;-globin mutant polypeptides comprise the amino acid sequence of normal human &bgr;-globin modified by (i) the substitution or deletion of Cys at amino acid positions 93 and 112, and (ii) the substitution of a Cys fore a non-Cys amino acid at one other position in the polypeptide, preferable Ser at amino acid position 9. Modified human hemoglobins containing this or other &bgr;-globin mutations, and/or an &agr;-globin mutation, are provided, as well as polymers of such modified hemoglobins. Nucleic acids, vectors, and transformed host cells for producing the &bgr;-globin mutants are provided.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: August 24, 2004
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventor: Clara Fronticelli
  • Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof
    Patent number: 6767889
    Abstract: Two-chain high molecular weight kininogen, and peptide analogs thereof having homology to sites within kininogen domain 5, are potent inhibitors of angiogenesis. The peptides have the formula X1-His-Lys-X-Lys-X2 wherein X is any amino acid, X1 is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids, and X2 is from zero to twelve amino acids, more preferably from zero to six amino acids, most preferably from zero to three amino acids. X is preferably an amino acid having a nonpolar side chain, or a polar side chain which is uncharged at pH 6.0 to 7.0. X is most preferably Asn, Phe or His. Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.
    Type: Grant
    Filed: November 9, 1999
    Date of Patent: July 27, 2004
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventor: Keith R. McCrae
  • Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
    Patent number: 6767926
    Abstract: Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the cytotoxic side effects of two classes of anticancer chemotherapeutics. Administration of a cytoprotective sulfone compound to a patient prior to anticancer chemotherapy with a mitotic phase cell cycle inhibitor or topoisomerase inhibitor reduces or eliminates the cytotoxic side effects of the anticancer agent on normal cells. The cytoprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increasing the dosage of the anticancer chemotherapeutic.
    Type: Grant
    Filed: October 11, 2000
    Date of Patent: July 27, 2004
    Assignee: Temple University - Of The Commonwealth System of Higher Education
    Inventors: Stephen C. Cosenza, M. V. Ramana Reddy, E. Premkumar Reddy
  • (E)-styryl sulfone anticancer agents
    Patent number: 6762207
    Abstract: (E)-styryl benzylsulfones of formula I are useful as anticancer agents: wherein R1, R2, R3, and R4 are independently selected from the group consisting of hydrogen, fluoro, chloro, iodo, bromo, C1-C6 alkyl, C1-C4 alkoxy, nitro, cyano and trifluoromethyl, with the proviso that (a) R1, R2, and R3 not all hydrogen when R4 is 2-chloro or 4-chloro; (b) when R1 and R3 are hydrogen and R2 is 4-bromo or 4-chloro, then R4 may not be 4-chloro, 4-fluoro or 4-bromo; (c) when R1 and R3 are hydrogen and R2 is 4-fluoro, then R4 may not be 4-fluoro or 4-bromo; (d) when R1 is hydrogen, and R4 is 2-fluoro, the R2 and R3 may not be 4-fluoro; and (e) when R1 is hydrogen and R3 is 4-hydrogen, 4-chloro, 4-bromo, 4-methyl or 4-methoxy, and R4 is 2-hydrogen, 2-chloro, or 2-fluoro; then R2 may not be 4-hydrogen, 4-chloro, 4-fluoro, or 4-bromo.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: July 13, 2004
    Assignee: Temple University - of the Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • Reversal of proinflammatory response by ligating the macrophage FcgammaRI receptor
    Publication number: 20040062763
    Abstract: Ligation of the Fc&ggr; receptor type I (Fc&ggr;RI) on IL-10-producing cells leads to a selective upregulation of IL-10 production, which in turn induces a marked suppression of IL-12 biosynthesis by IL-12-producing cells, particularly macrophages. The ligation of the Fc&ggr;RI receptor thus downmodulates IL-12 production via a mechanism that is dependent on macrophage-derived IL-10. Agents for ligating Fc&ggr;RI comprise, for example, multivalent antibodies which bind the Fc&ggr;RI receptor, immune complexes comprising antibodies which contain the Fc region of IgG, and IgG multimers, preferably IgG dimers and trimers. The ligating agent may be administered to therapeutically inhibit proinflammatory immune responses. In particular, the ligating agent may be administered to treat or prevent endotoxic shock associated with bacterial endotoxemia, and to treating autoimmune disorders.
    Type: Application
    Filed: September 19, 2003
    Publication date: April 1, 2004
    Applicant: Temple University - Of The Commonwealth System of Higher Education
    Inventors: David M. Mosser, Fayyaz Sutterwala
  • Method for protecting cells and tissues from ionizing radiation toxicity with &agr;, &bgr; unsaturated aryl sulfones
    Patent number: 6667346
    Abstract: Pre-treatment with &agr;,&bgr; unsaturated aryl sulfones protects normal cells from the toxic side effects of ionizing radiation. Administration of a radioprotective &agr;,&bgr; unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces the cytotoxic side effects of the radiation on normal cells. The radioprotective effect of the &agr;,&bgr; unsaturated aryl sulfone allows the clinician to safely increase the dosage of anticancer radiation. In some instances, amelioration of toxicity following inadvertent radiation exposure may be mitigated with administration of &agr;,&bgr; unsaturated arylsulfone.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: December 23, 2003
    Assignees: Temple University - Of The Commonwealth System of Higher Education, Onconova Therapeutics, Inc.
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy, Stephen C. Cosenza, Lawrence Helson
  • Reversal of proinflammatory response by ligating the macrophage Fc&ggr;RI receptor
    Patent number: 6660266
    Abstract: Ligation of the Fc&ggr; receptor type I (Fc&ggr;RI) on IL-10-producing cells leads to a selective upregulation of IL-10 production, which in turn induces a marked suppression of IL-12 biosynthesis by IL-12-producing cells, particularly macrophages. The ligation of the Fc&ggr;RI receptor thus downmodulates IL-12 production via a mechanism that is dependent on macrophage-derived IL-10. Agents for ligating Fc&ggr;RI comprise, for example, multivalent antibodies which bind the Fc&ggr;RI receptor, immune complexes comprising antibodies which contain the Fc region of IgG, and IgG multimers, preferably IgG dimers and trimers. The ligating agent may be administered to therapeutically inhibit proinflammatory immune responses. In particular, the ligating agent may be administered to treat or prevent endotoxic shock associated with bacterial endotoxemia, and to treating autoimmune disorders.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: December 9, 2003
    Assignee: Temple University - of The Commonwealth System of Higher Education
    Inventors: David M. Mosser, Fayyaz Sutterwala
  • (Z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors
    Patent number: 6656968
    Abstract: Compounds of the formula are provided wherein R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, C1-C8 alkyl, C1-C6 alkoxy, nitro, cyano, acetoxy, amino, carboxy, sulfamyl, lower acylsulfamyl and trifluoromethyl. The compounds are inhibitors of cyclooxygenase-2 activity, useful for treating inflammation and cyclooxygenase-mediated disorders.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: December 2, 2003
    Assignee: Temple University - Of the Commonwealth System of Higher Education
    Inventors: E. Premkumar Reddy, M. V. Ramana Reddy
  • (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof
    Patent number: 6656973
    Abstract: Provided are the compound (E)-4-carboxystyryl-4-chlorobenzyl sulfone, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: December 2, 2003
    Assignee: Temple University - Of the Commonwealth System of Higher Education
    Inventors: Stephen C. Cosenza, M. V. Ramana Reddy, E. Premkumar Reddy